Court finds 'ESIRAFT' deceptively similar to 'RACIRAFT,' prioritizing public health safety in pharmaceutical trademarks.
In a significant ruling, the Bombay High Court has granted an injunction in favor of Sun Pharmaceutical Industries Ltd. against Meghmani Lifesciences Ltd. The division bench comprising Justices Bharati Dangre and Manjusha Deshpande found the trademark 'ESIRAFT' used by Meghmani Lifesciences to be deceptively similar to Sun Pharmaceutical's trademark 'RACIRAFT.' This decision emphasizes the strict scrutiny applied to pharmaceutical trademarks, considering the potential risk to public health due to trademark confusion.
Sun Pharmaceutical, India's leading pharmaceutical company, had initially coined and registered the trademark 'RACIRAFT' for a medication used to treat heartburn and indigestion. The company sought legal recourse when it discovered Meghmani Lifesciences marketing a similar product under the trademark 'ESIRAFT.' Sun Pharmaceutical argued that the phonetic and visual similarities between the two trademarks could lead to consumer confusion, posing significant public health risks.
The court meticulously analyzed the trademarks under the provisions of the Trade Marks Act, 1999, focusing on phonetic similarity and the potential for confusion in hurried or imperfect pronunciation. Relying on precedents such as the Supreme Court's ruling in Cadila Health Care Ltd. v. Cadila Pharmaceuticals Ltd., the bench emphasized the heightened standards for evaluating trademark similarity in the pharmaceutical sector due to the serious implications for consumer safety.
Justice Dangre, delivering the judgment, highlighted that even slight phonetic similarities in pharmaceutical trademarks warrant injunctions due to the risk of consumers mistakenly receiving the wrong medication. The court dismissed the argument that visual dissimilarities and different packaging could mitigate the confusion, stating that the potential for mispronunciation and imperfect recollection in a multilingual society could lead to serious health consequences.
This ruling overturns an earlier decision by a single judge, which had vacated an ad-interim injunction against Meghmani Lifesciences. The division bench's decision reinstates the injunction, barring Meghmani Lifesciences from using the 'ESIRAFT' trademark and any variants similar to Sun Pharmaceutical's 'RACIRAFT.'
The judgment underscores the court's commitment to protecting public health by enforcing stringent trademark standards in the pharmaceutical industry. Legal experts note that this decision reinforces the importance of careful trademark selection and registration in the pharmaceutical sector to avoid potential conflicts and ensure consumer safety.
Bottom Line:
Trademark law concerning pharmaceutical products - Phonetic similarity between trademarks "RACIRAFT" and "ESIRAFT" deemed deceptively similar, warranting injunction due to potential confusion and public health risks.
Statutory provision(s): Trade Marks Act, 1999 Section 29, Trade Marks Act, 1999 Section 27
